Exbio — Research products — Antibodies — Cytoskeleton and ECM — Anti-Cytokeratin 19 Purified

Anti-Cytokeratin 19 Purified

Regulatory status

RUO

Antigen

Cytokeratin 19

Clone

A53-B/A2

Format

Purified

Reactivity

Human

Application

ELISA, FC-IC, IP, WB, IHC-P, ICC

Variant

0.1 mg

11-120-C100

In stock

154.00 USD

0.025 mg

11-120-C025

Delivery 1 week

77.00 USD

Variant

0.1 mg

11-120-C100

In stock

154.00 USD

0.025 mg

11-120-C025

Delivery 1 week

77.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG2a

Specificity

The mouse monoclonal antibody A53-B/A2 recognizes the rod domain of cytokeratin 19 (40 kDa), an intracellular antigen constituting intermmediate cytoskeleton filaments. Cytokeratin 19 is not expressed in hepatocytes; it is often co-expressed with cytokeratin 7.

Application

ELISA, FC-IC, IP, WB, IHC-P, ICC

Application details

Flow cytometry: Recommended dilution: 1-5 μg/ml. Intracellular staining.
Immunohistochemistry: Recommended dilution: 5-10 μg/ml.
Western blotting: Recommended dilution: 1-2 μg/ml, positive control: MCF-7, BA-17, HT-29 cells.

Reactivity

Human

Immunogen

MCF-7 human breast adenocarcinoma cell line

Concentration

1 mg/ml

Preparation

Purified by protein-A affinity chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

K19, CK19, CYK19, KRT19, K1CS

Antigen description

Cytokeratins are a subfamily of intermediate filaments and characterized by remarkable biochemical diversity. They are represented in epithelial tissues by at least 20 different polypeptides, molecular weight between 40 kDa and 68 kDa. The individual cytokeratin polypeptides are designated 1 to 20 and divided into the type I (acidic cytokeratins 9-20) and type II (basic to neutral cytokeratins 1-8) families.

Entrez Gene ID 3880

UniProt ID P08727

Immunohistochemistry staining (paraffin sections) of cytokeratin 19 in human liver using mouse monoclonal antibody A53-B/A2 (11-120-C100, diluted 1:100), detected with GAM IgG-Alexa Fluor®488 (diluted 1:200; green), cell nuclei stained with PI (1µg/ml; orange).

Separation of MCF-7 cells (red-filled) from human leukocytes (black-dashed) in flow cytometry analysis (intracellular staining) of peripheral whole blood spiked with MCF-7 cells stained using anti-Cytokeratin 19 (A53-B/A2) purified antibody (concentration in sample 3 μg/ml, GAM APC).

Flow cytometry intracellular staining pattern of human peripheral whole blood spiked with MCF-7 cells stained using anti-Cytokeratin 19 (A53-B/A2) purified antibody (concentration in sample 3 μg/ml, GAM APC).

Immunohistochemistry staining of human prostate (paraffin sections) using anti-cytokeratin 19 (A53-B/A2). Commercially tested by LifeSpan BioSciences.

Anti-Hu Cytokeratin 19 Purified (clone A53-B/A2) reactivity pattern in WB application.
The reactivity of A53-B/A2 antibody was assessed by comparing binding signals in a panel of cytokeratin-positive and cytokeratin-negative human cell lines. Western blotting analysis was performed on whole cell extracts (hot 1% SDS lysis buffer) of MCF-7, Hep-G2, HT-29, HeLa, and Jurkat cell lines, mixed and heated (100°C, 5 min) with reducing (2-mercaptoethanol) SDS-loading buffer. Samples were resolved using 10% SDS-PAGE gel.

Nitrocellulose membrane blot was probed with mouse IgG2a monoclonal antibody A53-B/A2 (1 µg/ml), followed by IRDye 800CW Goat-anti-Mouse IgG (green). For multiplex fluorescent Western blot detection, mouse anti-GAPDH monoclonal antibody FF26A conjugated with DyLight 680 (0.1 µg/ml) was used as the loading control (red).

Cytokeratin 19 was detected at ~40 kDa in the respective cell lines.

Western blotting analysis of human cytokeratin 19 using mouse monoclonal antibody A53-B/A2 on lysates of HT-29 cell line and Jurkat cell line (cytokeratin non-expressing cell line; negative control) under non-reducing and reducing conditions. Nitrocellulose membrane was probed with 2 µg/ml of mouse anti-cytokeratin 19 monoclonal antibody A53-B/A2 followed by IRDye800-conjugated anti-mouse IgG1 secondary antibody. A specific band was detected for cytokeratin 19 at approximately 40 kDa.

Product specific references:

Karsten U, Papsdorf G, Roloff G, Stolley P, Abel H, Walther I, Weiss H: Monoclonal anti-cytokeratin antibody from a hybridoma clone generated by electrofusion. Eur J Cancer Clin Oncol. 1985 Jun;21(6):733-40.
PubMed

Kasper M, Moll R, Stosiek P, Karsten U: Patterns of cytokeratin and vimentin expression in the human eye. Histochemistry. 1988;89(4):369-77.
PubMed

Bártek J, Bártková J, Taylor-Papadimitriou J, Rejthar A, Kovarík J, Lukás Z, Vojtĕsek B: Differential expression of keratin 19 in normal human epithelial tissues revealed by monospecific monoclonal antibodies. Histochem J. 1986 Oct;18(10):565-75.
PubMed

Quardokus EM, Saunders DC, McDonough E, Hickey JW, Werlein C, Surrette C, Rajbhandari P, Martinez Casals A, Tian H, Lowery L, Neumann EK, Björklund F, Neelakantan TV, Croteau J, Wiblin AE, Fisher J, Livengood AJ, Dowell KG, Silverstein JC, Spraggins JM, Pryhuber GS, Deutsch G, Ginty F, Nolan GP, Melov S, Jonigk D, Caldwell MA, Vlachos IS, Mueller W, Gehlenborg N, Stockwell BR, Lundberg E, Snyder MP, Germain RN, Camarillo JM, Kelleher NL, Börner K, Radtke AJ: Organ mapping antibody panels: a community resource for standardized multiplexed tissue imaging. Nat Methods 2023 Aug;20(8):1174-1178. doi: 10.1038/s41592-023-01846-7.
PubMed